Efficacy of autologous hematopoietic stem cell transplantation on the treatment of patients with acute myeloid leukemia
10.3969/j.issn.1674-7445.2018.01.009
- VernacularTitle:自体造血干细胞移植治疗急性髓系白血病的疗效观察
- Author:
Yanling SUN
1
;
Jingwen ZHANG
;
Zhigang FANG
Author Information
1. 中山大学附属第三医院血液内科 中山大学血液病研究所
- Keywords:
Acute myeloid leukemia (AML);
Autologous hematopoietic stem cell transplantation (auto-HSCT);
Minimal residual disease (MRD);
Hematopoietic reconstitution;
Peripheral blood hematopoietic stem cell;
Septicemia;
Cytomegalovirus viremia;
Disease-free survival
- From:
Organ Transplantation
2018;9(1):63-68
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy of autologous hematopoietic stem cell transplantation on the treatment of patients with acute myeloid leukemia (AML) in complete remission stage. Methods Clinical data of 14 AML patients underwent autologous hematopoietic stem cell transplantation were analyzed retrospectively, including 7 low-risk patients, 6 moderate-risk patients and 1 high-risk patient. After pretreatment, pre-cryopreserved autologous peripheral blood stem cells were retransfused. And component blood transfusion, increasing white blood cell (WBC) count and preventing from infection, etc. were given. Hematopoietic reconstitution of autologous stem cells in the patients was observed, and incidence of transplantation related complications was obtained. Furthermore, survival curves were drawn, and postoperative 1- and 3-year overall survival rates and disease-free survival (DFS) rates were calculated. Results Hematopoietic reconstitution was achieved in all 14 patients. The median time of WBC implantation was 12(9-28) d, and that of platelet implantation was 29(8-158) d. Two patients suffered from E. coli septicemia during neutropenia stage, 1 from proteus vulgaris septicemia, 1 from cytomegalovirus viremia within 29 d after transplantation and the remaining from infection or gastrointestinal reaction after pretreated. All patients were cured by anti-infection and other symptomatic relief and supportive treatment. All patients were followed up for 29.8(5.3-61.5) months. In 14 patients, 5 cases recurred. 11 patients survived and 3 died of recurrence. The postoperative 1- and 3-year overall survival rates were 86％ and 79％, and the postoperative 1- and 3-year DFS rates were 64％ and 57％. Conclusions Autologous hematopoietic stem cell transplantation is effective in the treatment of majority patients with low- or moderate-risk AML.
